PPBT (Purple Biotech) Stock Based Compensation : $0.58 Mil (TTM As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Purple Biotech Stock Based Compensation?

Purple Biotech's Stock Based Compensation for the three months ended in Dec. 2024 was $-0.03 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 was $0.58 Mil.

Purple Biotech Stock Based Compensation Historical Data

The historical data trend for Purple Biotech's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Purple Biotech Stock Based Compensation Chart

Purple Biotech Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Stock Based Compensation

Get a 7-Day Free Trial

2.65

2.08

2.41

1.88

0.58

Purple Biotech Quarterly Data
	Jun19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Stock Based Compensation	Get a 7-Day Free Trial															0.18	0.27	0.22	0.13	-0.03

Purple Biotech Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.58 Mil.

Purple Biotech Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Purple Biotech's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

Purple Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Purple Biotech Ltd (NAS:PPBT) » Definitions » Stock Based Compensation

Comparable Companies

Traded in Other Exchanges

PPBT:Israel

Address

4 Oppenheimer Street, Science Park, Rehovot, ISR, 7670104

Website

https://www.purple-biotech.com

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.